Zentalis appoints Shannon Campbell as Class I director, expanding board to 7 members

Zentalis Pharmaceuticals, Inc.

Board increased from 6 to 7 directors; Campbell appointed as Class I director effective May 22, 2026.
Annual retainer of $45,000 for board service plus $7,500 for Compensation Committee membership.
Granted RSUs covering 114,200 shares on May 26, 2026, vesting one-third annually over three years.
After 6 months, eligible for annual equity grant of RSUs covering 0.08% of outstanding shares.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Shannon Campbell

Director

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2026-05-22
Filed: May 27, 2026, 4:07 PM ET

Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shannon Campbell was appointed as Director at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-26-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.